IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens

Table 2

Baseline characteristics and treatment response in 141 patients treated with peginterferon plus ribavirin according to IFNL4 ss469415590 variant.

	IFNL4 major,	IFNL4 minor,	values (major versus minor groups)
Gender, male/female	46/47	25/23	0.900
Age, years	56.1 ± 11.7	54.7 ± 10.6	0.488
Previous treatment: naïve/relapse/null	68/19/6	29/7/12	0.0042
AST, IU/L	53.4 ± 48.5	65.0 ± 44.0	0.167
ALT, IU/L	65.1 ± 64.9	82.0 ± 63.3	0.14
γ-GTP, IU/L	40.9 ± 39.2	87.5 ± 98.9	0.000107
Hemoglobin, g/dL	13.9 ± 1.2	14.2 ± 1.2	0.16
Platelets, ×10^4/mm^3	16.8 ± 5.7	16.8 ± 6.1	1.00
Treatment response
RVR,	15	0	0.0079
EVR,	59	5	<0.0001
SVR/relapse/null	60/23/10	10/12/25	<0.0001

Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.